Upgrade to see committee overlap, performance context, and full expert analysis.
ZBRA congressional trades
7 matched disclosures
ZBRA congressional trades snapshot
This page summarizes public STOCK Act disclosures involving ZBRA. It is useful for seeing which lawmakers reported ZBRA transactions, how many filings are visible, the buy/sell mix, and whether the newest public filing describes a recent or delayed trade.
Jun 18, 2025
Public House and Senate STOCK Act disclosures normalized by Congressional Trader.
Filing date can trail transaction date. This page is for research and monitoring, not investment advice.
What the ZBRA congressional trade page shows
Congressional Trader tracks 7 public STOCK Act disclosures for ZBRAacross 3 lawmakers. This page separates purchases from sales, shows filing delays, and links each disclosure back to the individual politician profile when available.
The most recent ZBRA filing shown here was filed on Jun 18, 2025 by Kelly Morrison as a sale. Related lawmakers include Kelly Morrison, John James, Robert P. Bresnahan.
Top lawmakers for ZBRA
Pro performance summary
Unlock 30/90-day post-trade summaries, committee overlap, and CSV-oriented research views for high-intent ticker research.
Compare Pro plansUpgrade to see committee overlap, performance context, and full expert analysis.
Upgrade to see committee overlap, performance context, and full expert analysis.
Upgrade to see committee overlap, performance context, and full expert analysis.
Upgrade to see committee overlap, performance context, and full expert analysis.
Upgrade to see committee overlap, performance context, and full expert analysis.
Upgrade to see committee overlap, performance context, and full expert analysis.
FAQ
Which lawmakers traded ZBRA?
Recent ZBRA disclosures include Kelly Morrison, John James, Robert P. Bresnahan.
What is the buy/sell mix for ZBRA?
The visible sample currently shows 1 purchases and 6 sales or partial sales.
Should I trade based on ZBRA disclosures?
No. This page summarizes public filings for research and monitoring. It is not investment advice.